Stem Cells Translational Medicine

Papers
(The H4-Index of Stem Cells Translational Medicine is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Compliance in Non-Clinical Development of Cell-, Gene-, and Tissue-Based Medicines: Good Practice for Better Therapies116
Front Cover104
Invasive therapy for children with autism is not justified96
Expanded Access Protocol of Umbilical Cord Blood Infusion for Children with Neurological Conditions: An Update69
Results of a Multicenter Evaluation of a Rapid Flow Cytometry Potency Assay for Cryopreserved Cord Blood Units: A BEST Collaborative Study69
18 Years of Cord Blood Banking in Ukraine: Current Status and Future Prospects54
Optimization of T-Cell Suppression Potency Assay for Human Cord Tissue Mesenchymal Stromal Cells53
Identification and Successful Re-Consent of Existing Cord Blood Donors for the Creation of Induced Pluripotent Stem Cell Lines51
Safety of Combined Autistic Spectrum Disorders Treatment with Umbilical Cord Mesenchymal Stem Cells Application: Clinical Investigation41
Hyaline Cartilage Microtissues Engineered from Adult Dedifferentiated Chondrocytes: Safety and Role of WNT Signaling39
Improving the future of clinical trials and translation of mesenchymal stromal cell therapies for neonatal disorders38
Transcriptomic analysis reveals the anti-cancer effect of gestational mesenchymal stem cell secretome37
Correction to: Partial Tendon Injury at the Tendon-to-Bone Enthesis Activates Skeletal Stem Cells37
Abstract 5 Human Umbilical Cord Blood-Derived Cell Therapy Product, DUOC-01, Promotes Remyelination by Driving the Differentiation of Oligodendrocyte Progenitor Cells35
Safety of Stromal Vascular Fraction Cell Therapy for Chronic Kidney Disease of Unknown Cause (Mesoamerican Nephropathy)35
Correction to: Allogenic Umbilical Cord-Derived Mesenchymal Stromal Cells Sustain Long-Term Therapeutic Efficacy Compared With Low-Dose Interleukin-2 in Systemic Lupus Erythematosus31
Issue Information31
Glucose Oxidase Induces Mobilization of Long-Term Repopulating Hematopoietic Cells in Mice31
A Preview of Selected Articles—September 202128
Cell Therapy Improves Quality-of-Life in Heart Failure: Outcomes From a Phase III Clinical Trial27
27
A preview of selected articles26
Correction to: Sstr2 Defines the Cone Differentiation-Competent Late-Stage Retinal Progenitor Cells in the Developing Mouse Retina26
Human In Vitro Models of Neuroenergetics and Neurometabolic Disturbances: Current Advances and Clinical Perspectives26
Mesenchymal stromal cell delivery via an ex vivo bioreactor preclinical test system attenuates clot formation for intravascular application26
Dll4 Inhibition Promotes Graft Retention in Fat Grafting Enriched with Adipose-Derived Stem Cells25
An Urgent Need for Standardization of Stem Cells and Stem Cell-derived Products Toward Clinical Applications25
Patient-Specific iPSC-Derived Models Link Aberrant Endoplasmic Reticulum Stress Sensing and Response to Juvenile Osteochondritis Dissecans Etiology25
0.0226891040802